Replies to post #35930 on Intellipharmaceutics International Inc. (IPCI)

[wimuskyfisherman]

Angelo- Please call Dr. Odidi and tell him your feelings on this. It seems to me he is unwilling to partner anything and would just rather sell 25% of the company for cash to fund another quarter.

[TRENDmendous]

Yep an announcement of a partnership is what we NEED badly! From their Jan 24th Operation update you would think we should/could have heard about one by now/soon!

Intellipharmaceutics continues to pursue partnering opportunities of its other ANDA, Abbreviated New Drug Submission (“ANDS”) and NDA products and product candidates, both in the U.S. and internationally. The Company has a strong pipeline of ANDAs. Two ANDAs have recently been approved and others are in various stages of the FDA review process. While commercialization opportunities for our product have been challenging in the U.S. due to the extremely competitive cost environment, the Company has been working with its supply partners to reduce input costs and achieve efficiencies which we expect to lead to new opportunities in the U.S.

In addition, the Company continues efforts to identify opportunities overseas, including in China, that could if effectuated provide product distribution alternatives through partnerships and therefore do not require an investment or asset acquisition by the Company. The Company recently visited China where discussions toward establishing a partnership to facilitate future development activities are ongoing. The Company has not entered into any such arrangements at this time. These opportunities could involve out-licensing of our products, third-party manufacturing supply and more efficient access to pharmaceutical ingredients and therefore assist with the development of our growing product pipeline.

As the Company builds its product portfolio, we are also seeking to add additional product development candidates to our pipeline. We have received considerable interest and are investigating several opportunities to develop products in collaboration with international partners.

[Samsa]

Angelo, I agree with your comments. I was merely pointing out that if they really needed cash to get through the next year, by inking a deal for both even without upfront payments, they could be achieved with a RS and then a minimal dilution.

It was only an example. I too would rather not see the RS and just make due, but my thinking is, they won't trust if we sit at $3 a share and then they sell an offering that were not sold back down below $1. So my gut tells me they RS and then hence the example I laid out.